Cargando…

Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes

BACKGROUND: Glycated hemoglobin (HbA1c) is accepted as the most reliable marker for assessing chronic glycemia. The present study aimed to investigate glycemic control in cardiovascular outcome trials (CVOTs) performed by pharmaceutical sponsors, at the request of the United States Food and Drug Adm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimazawa, Rumiko, Ikeda, Masayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859615/ https://www.ncbi.nlm.nih.gov/pubmed/31832207 http://dx.doi.org/10.1186/s40545-019-0193-y

Ejemplares similares

Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus
por: Ikeda, Masayuki, et al.
Publicado: (2019)

Are there any differences in the regulations of personalized medicine among the USA, EU and Japan?
por: Shimazawa, Rumiko, et al.
Publicado: (2013)

Approval status and evidence for WHO essential medicines for children in the United States, United Kingdom, and Japan: a cross-sectional study
por: Shimazawa, Rumiko, et al.
Publicado: (2017)

Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
por: Shimazawa, Rumiko, et al.
Publicado: (2021)

Natural language processing‐based assessment of consistency in summaries of product characteristics of generic antimicrobials
por: Shimazawa, Rumiko, et al.
Publicado: (2018)

Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits
por: McGuire, Darren K., et al.
Publicado: (2021)

Tight Glycemic Control and Cardiovascular Effects in Type 2 Diabetic Patients
por: Moodahadu, Latha Subramanya, et al.
Publicado: (2014)

The association between glycemic variability and diabetic cardiovascular autonomic neuropathy in patients with type 2 diabetes
por: Jun, Ji Eun, et al.
Publicado: (2015)

Effects of Melatonin on Glycemic Variability in Type 2 Diabetes Mellitus: Protocol for a Crossover, Double-Blind, Placebo-Controlled Trial
por: Martorina, Wagner, et al.
Publicado: (2023)

Glycemic variability and cardiovascular disease in patients with type 2 diabetes
por: Martinez, Marcela, et al.
Publicado: (2021)

Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications
por: Huri, Hasniza Zaman, et al.
Publicado: (2015)

Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta‐Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials
por: Giugliano, Dario, et al.
Publicado: (2019)

Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial
por: Lachin, John M., et al.
Publicado: (2017)

Prolonged Exercise in Type 1 Diabetes: Performance of a Customizable Algorithm to Estimate the Carbohydrate Supplements to Minimize Glycemic Imbalances
por: Francescato, Maria Pia, et al.
Publicado: (2015)

Effect of Group Medical Appointments on Glycemic Control of Patients With Type 2 Diabetes
por: Caballero, Cora A., et al.
Publicado: (2015)

Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials
por: Giorgino, Francesco, et al.
Publicado: (2013)

Relationship Between Baseline Glycemic Control and Cognitive Function in Individuals With Type 2 Diabetes and Other Cardiovascular Risk Factors: The Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) trial
por: Cukierman-Yaffe, Tali, et al.
Publicado: (2009)

Impact of Glycemic and Blood Pressure Variability on Surrogate Measures of Cardiovascular Outcomes in Type 2 Diabetic Patients
por: Di Flaviani, Alessandra, et al.
Publicado: (2011)

Associations of Glycemic Control With Cardiovascular Outcomes Among US Hemodialysis Patients With Diabetes Mellitus
por: Rhee, Jinnie J., et al.
Publicado: (2017)

Revisiting clinical trials on glycemic control and cardiovascular risk
por: Ferreira, Sandra Roberta Gouvea
Publicado: (2009)

Glycemic control and correlates in a group of sub Saharan type 1 diabetes adolescents
por: Djonou, Cathy, et al.
Publicado: (2019)

Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial
por: Strojek, Krzysztof, et al.
Publicado: (2014)

Nigella sativa Improves Glycemic Control and Ameliorates Oxidative Stress in Patients with Type 2 Diabetes Mellitus: Placebo Controlled Participant Blinded Clinical Trial
por: Kaatabi, Huda, et al.
Publicado: (2015)

Glycemic control and lipid outcomes in children and adolescents with type 2 diabetes
por: Barr, Mary Margaret, et al.
Publicado: (2019)

Factors associated with glycemic control and diabetes complications in a group of Saudi patients with type 2 diabetes
por: Ewid, Mohammed, et al.
Publicado: (2023)

Relationship between vitamin D status, glycemic control and cardiovascular risk factors in Brazilians with type 2 diabetes mellitus
por: Rolim, Maria Creusa, et al.
Publicado: (2016)

Relevance of the Glycemic Index and Glycemic Load for Body Weight, Diabetes, and Cardiovascular Disease
por: Vega-López, Sonia, et al.
Publicado: (2018)

Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial
por: Wanner, Christoph, et al.
Publicado: (2021)

Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression
por: Maiorino, Maria Ida, et al.
Publicado: (2021)

Inequalities in glycemic and multifactorial cardiovascular control of type 2 diabetes: The Heart Healthy Hoods study
por: Ares-Blanco, Sara, et al.
Publicado: (2022)

Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial
por: Shah, Hetal S., et al.
Publicado: (2016)

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
por: Ferrannini, Ele, et al.
Publicado: (2010)

Effects of CoQ10 Supplementation on Lipid Profiles and Glycemic Control in Patients with Type 2 Diabetes: a randomized, double blind, placebo-controlled trial
por: Zahedi, Hoda, et al.
Publicado: (2014)

A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control
por: Gantz, Ira, et al.
Publicado: (2017)

Depression, glycemic control and type 2 diabetes
por: Papelbaum, Marcelo, et al.
Publicado: (2011)

Glycemic Variability and Oxidative Stress: A Link between Diabetes and Cardiovascular Disease?
por: Saisho, Yoshifumi
Publicado: (2014)

Intensive Glycemic Control Improves Long-term Renal Outcomes in Type 2 Diabetes in the Veterans Affairs Diabetes Trial (VADT)
por: Agrawal, Lily, et al.
Publicado: (2019)

Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
por: Hinnen, Deborah, et al.
Publicado: (2019)

Impact of an integrated care program on glycemic control and cardiovascular risk factors in patients with type 2 diabetes in Saudi Arabia: an interventional parallel-group controlled study
por: Tourkmani, Ayla M., et al.
Publicado: (2018)

The effect of acorn muffin consumption on glycemic indices and lipid profile in type 2 diabetic patients: A randomized double‐blind placebo‐controlled clinical trial
por: Sasani, Najmeh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p2qrqg4gpt809hcl2bsvl1lbaa